CRBU — Caribou Biosciences Share News
0.000.00%
Last trade - 00:00- $57.12m
- -$55.19m
- $11.16m
Brief: Caribou Biosciences Announces $25 Mln Equity Investment From Pfizer
U.S. STOCKS ON THE MOVE-First Horizon, Fidelity National, Caribou Biosciences
Caribou up on Pfizer's $25 million equity investment
Brief: Caribou Biosciences Co, Pfizer Also Entered Into Information Rights Agreement On June 29 Having A 36-Month Term
Brief: Caribou Biosciences Presents New Preclinical Data On Cb-012, An Allogeneic Anti-Cll-1 Car-T Cell Therapy, At The 2023 Aacr Annual Meeting
Brief: Caribou Biosciences Initiates Dose Expansion Portion Of CB-010 ANTLER Phase 1 Trial In Second-Line LBCL Patients
Brief: Caribou Biosciences Announces Dosing Of First Patient In The CaMMouflage Phase 1 Trial Of CB-011
U.S. RESEARCH ROUNDUP- Ameresco, Bioxcel Therapeutics, Roblox
Brief: Caribou Biosciences Reports Fourth Quarter And Full Year 2022 Financial Results
Brief: Caribou Biosciences Q4 loss per share USD 0.44
Brief: Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress
Brief: Caribou Biosciences Selects ROR1 As Target For CB-020
Caribou rises as FDA grants cancer therapy RMAT status, fast-track tag
Brief: Caribou Biosciences Announces The FDA Granted Regenerative Medicine Advanced Therapy (Rmat) And Fast Track Designations To Cb-010, An Allogeneic Anti-Cd19 Car-T Cell Therapy
Caribou Biosciences up on FDA nod for cancer therapy
Brief: Caribou Biosciences Announces FDA Clearance Of Ind Application For Cb-011, An Allogeneic Anti-Bcma Car-T Cell Therapy For The Treatment Of Relapsed Or Refractory Multiple Myeloma
Brief: Caribou Biosciences Reports Third Quarter 2022 Financial Results, Provides Business Update
Brief: Caribou Biosciences Presents Case Report On Long-Term Follow Up Of First Patient Dosed In Phase 1 Antler Trial
Brief: Caribou Biosciences Inc - Entered Into An Open Market Sale Agreement To Issue And Sell Up To $100.0 Million Of Company's Shares Of Common Stock